Release time：Mar 07, 2024
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held in San Diego, USA, from April 5-10, 2024.
The AACR Annual Meeting is one of the largest cancer research conferences in the world. The synopses have been published on the AACR official website.
Poster Presentation
01
Abstract title: Disrupting IL-11/IL-11R signaling by an efficacious anti-IL-11 antibody 9MW3811 enhances T cell tumor infiltration and synergizes with anti-PD-1 therapies in vivo
Abstract Number: 2365
Location: Poster Section 38
Poster Board Number: 11
Session Date and Time: Apr 8, 2024 9:00 AM - 12:30 PM PDT
02
Abstract title: 2MW4991, a novel ADCC-enhanced integrin αvβ8 blocker, exhibits high anti-tumor potency and was well tolerated in cynomolgus monkeys
Abstract Number: 6349
Location: Poster Section 41
Poster Board Number: 10
Session Date and Time: Apr 9, 2024 1:30 PM - 5:00 PM PDT
03
Abstract title: 2MW4691, a novel CCR8/CTLA-4 bispecific antibody, displays potent anti-tumor efficacy by specifically depleting tumor-infiltrating Tregs and blocking CTLA-4 signaling on CD8+ T cells
Abstract Number: 6350
Location: Poster Section 41
Poster Board Number: 10
Session Date and Time: Apr 9, 2024 1:30 PM - 5:00 PM PDT
About 9MW3811
9MW3811 is a high-affinity humanized neutralizing antibody against IL-11. It is currently undergoing Phase 1 clinical trials in Australia and China. IL-11 is an important inflammation factor that plays a crucial role in fibrosis and the development and progression of tumors. Studies have shown that high expression of IL-11 is associated with the prognosis of various tumors such as lung cancer, liver cancer, and colorectal cancer. It has significant effects on various cells in the tumor microenvironment, including tumor cells, macrophages, T cells, and tumor-associated fibroblasts. 9MW3811 inhibits the activation of the downstream signaling pathway of IL-11 by blocking the binding of IL-11 to IL-11R, demonstrating good anti-tumor therapeutic effects in multiple preclinical pharmacodynamic models. When used in combination with anti-PD-1 antibodies, 9MW3811 significantly promotes the infiltration of CD8+ T lymphocytes, improving the T cell exhaustion caused by anti-PD-1 antibodies, thereby showing better combined anti-tumor efficacy.
About 2MW4991
2MW4991 is a high-specificity, high-affinity ADCC-enhanced antibody targeting integrin αvβ8. Integrin αvβ8 is an important activator of TGF-β, specifically regulating the activity of TGF-β in immune cells. Studies have found that integrin αvβ8 is highly expressed in certain tumors, and blocking αvβ8 can completely inhibit the release of TGF-β. 2MW4991 exhibits strong anti-tumor activity in immune-excluded tumor models, significantly promoting immune cell infiltration in immune-excluded tumors and greatly increasing the sensitivity of immune-excluded tumors to PD1 inhibitors.
About 2MW4691
2MW4691 is an ADCC-enhanced bispecific antibody targeting CCR8/CTLA-4. CTLA-4 is expressed on both CD8+ T cells and Tregs, and targeting CTLA-4 has a strong anti-tumor effect, but its clinical application is limited due to strong side effects. CCR8 is a specific marker for tumor infiltrating Tregs, almost not expressed on other immune cells and peripheral Tregs. 2MW4691 retains high affinity for CCR8 and attenuated CTLA-4 targeting activity, specifically eliminating tumor-infiltrating Tregs and blocking the immunosuppression mediated by CTLA-4 signaling on peripheral CD8+ T cells. It demonstrates strong anti-tumor activity in preclinical transgenic animal models and shows good safety in primates.
